Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000231440 | SCV000285312 | benign | Tuberous sclerosis 2 | 2023-12-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001016356 | SCV001177304 | likely benign | Hereditary cancer-predisposing syndrome | 2020-12-14 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Genome- |
RCV000231440 | SCV002039679 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Centogene AG - |
RCV000231440 | SCV002059233 | uncertain significance | Tuberous sclerosis 2 | 2018-09-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003884383 | SCV004702788 | uncertain significance | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | TSC2: PM1, PP3, PS3:Supporting |